Advertisement

Drug Safety

, Volume 14, Issue 4, pp 219–227 | Cite as

Monoamine Oxidase Inhibitors

An Update on Drug Interactions
  • Martin G. Livingston
  • Hilary M. Livingston
Review Articles Drug Experience

Summary

After initial enthusiasm, the use of monoamine oxidase inhibitors (MAOIs) has been limited by the wide range of MAOI-drug and MAOI-food interactions that are possible, particularly with sympathomimetic medications or tyramine-containing foods, resulting in hypertensive reactions. Despite their clinical benefits, this has led to a reduction in use of such medications.

Discovery of the 2 main subgroups of monoamine oxidase, types A and B, led to the synthesis of MAOIs selective for one or other of these isoenzymes. Consequently, selegiline (deprenyl), a selective MAO-B inhibitor, was developed for the treatment of idiopathic Parkinson’s disease. This drug is useful in the treatment of the early stages of the disease and later on as an adjunct to other drug therapies. Although the selective MAO-A inhibitor, clorgiline (clorgyline), was found to be effective in the treatment of depression, it still retained the potential to cause hypertensive reactions.

Recently, agents that are not only selective, but reversible in their inhibition of MAO-A (RIMAs) have been synthesised (e.g. moclobemide and toloxatone), and have proven antidepressant efficacy. Whilst they are less likely to induce hypertensive reactions with the concomitant administration of sympathomimetic drugs or with tyramine-rich foodstuffs, it still seems wise to advocate care in co-prescribing potentially interacting medications and to advise a degree of caution with regard to the dietary intake of foodstuffs likely to contain a high tyramine content. Although these newer drugs represent an advance in safety, their use has, as yet, only been established in the treatment of depression. RIMAs also retain a potential for adverse interaction with other drugs. Concomitant prescription of serotonin-enhancing drugs should only be undertaken with caution for patients on moclobemide, toloxatone or selegiline. Coprescription of sympathomimetic drugs should also be avoided with these newer MAOIs and patients should be advised against purchasing over-the-counter preparations that may contain sympathomimetic drugs.

Keywords

Tyramine Selegiline Moclobemide Monoamine Oxidase Inhibitor Serotonin Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kline NS. Monoamine oxidase inhibitors: an unfinished picaresque tale. In: Ayd FG, Blackwell B, editors. Discoveries in biological psychiatry. Philadelphia: Lippincott, 1970: 194–204Google Scholar
  2. 2.
    Zeller EA, Barsky J. In vivo inhibition of liver and brain MAO by 1-izonicotinile-2-izopropyle-3-hydrosine. Proc Soc Exp BiolMed 1952; 81: 459–61PubMedGoogle Scholar
  3. 3.
    Johnston JP. Some observations on a new monoamine oxidase inhibitor in brain tissue. Biochem Pharmacol 1968; 17: 1285–97PubMedCrossRefGoogle Scholar
  4. 4.
    Rederer P, Youdim MBH, Rausch WD, et al. On the mode of action of 1-deprenyl in the human central nervous system. J Neural Transm 1978; 43: 217–26CrossRefGoogle Scholar
  5. 5.
    MAOIs move up the menu. Drug Ther Bull 1989; 27(16): 63–4Google Scholar
  6. 6.
    Bass C, Kerwin R. The rediscovery of MAOIs. BMJ 1989; 298: 345–6PubMedCrossRefGoogle Scholar
  7. 7.
    Shaw DM. A study of refractory cases of depressive illness and their response to combined anti-depressant treatment. Br J Psychiatry 1977; 130: 4–51Google Scholar
  8. 8.
    Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl 1989; 6: 38–45PubMedGoogle Scholar
  9. 9.
    Bazire S. Interactions with MAOIs. Pharm J 1986; 238: 417–9Google Scholar
  10. 10.
    Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991; 11(1): 55–9PubMedCrossRefGoogle Scholar
  11. 11.
    Sullivan E, Shulman KL. Diet monoamine oxidase inhibitors: a re-examination. Can J Psychiatry 1984; 29: 707–11PubMedGoogle Scholar
  12. 12.
    Sternbach H. Serotonin syndrome. Am J Psychiatry 1991; 148: 705–13PubMedGoogle Scholar
  13. 13.
    Pare CMD. The present status of MAOIs. Br J Psychiatry 1985; 146: 576–84PubMedCrossRefGoogle Scholar
  14. 14.
    Tyrer P. Towards rational therapy with MAOIs. Br J Psychiatry 1976; 128: 354–60PubMedCrossRefGoogle Scholar
  15. 15.
    Tollefson GD. MAOIs: a review. J Clin Psychiatry 1983; 44: 280–8PubMedGoogle Scholar
  16. 16.
    Freeman H. Moclobemide. Lancet 1993; 342: 1528–32PubMedCrossRefGoogle Scholar
  17. 17.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  18. 18.
    Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 1983; Suppl. 95: 57–80CrossRefGoogle Scholar
  19. 19.
    Mann JJ, Aarons SF, Wilner PJ, et al. Controlled study of the anti-depressant efficacy and side-effects of 1-deprenyl. Arch Gen Psychiatry 1989; 46: 45–50PubMedCrossRefGoogle Scholar
  20. 20.
    Sunderland E, Cohen RM, Malchan S, et al. High dose selegiline in treatment resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607–15PubMedCrossRefGoogle Scholar
  21. 21.
    Lecrubier Y. Risk benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug Saf 1994; 10(4): 292–300PubMedCrossRefGoogle Scholar
  22. 22.
    Lipper S, Murphy DL, Slater S, et al. Comparative behavioural effects of clorgyline and pargyline in man: a preliminary investigation. Psychopharmacol 1979; 62(2): 123–8CrossRefGoogle Scholar
  23. 23.
    Lader MH, Sakalin G, Tansella M. Interaction between sympathomimetic amines and a new MAOI. Psychopharmacologia 1972; 18: 118–23CrossRefGoogle Scholar
  24. 24.
    Livingston MG. Interactions with selective MAOIs. Lancet 1995; 345: 533–4PubMedCrossRefGoogle Scholar
  25. 25.
    ABPI data sheet compendium, 1995/96. London: Datapharma Publications Ltd, 1995: 334Google Scholar
  26. 26.
    McGrath PJ, Stewart JW, Quicken F. A possible 1-deprenyl induced hypertensive reaction. J Clin Psychopharmacol 1989; 9(4): 310–1PubMedCrossRefGoogle Scholar
  27. 27.
    ABPI data sheet compendium, 1995/96. London: Datapharma Publications Ltd, 1995: 1447–8Google Scholar
  28. 28.
    Dictionnairie Vidal 1993. Paris: OVP Editions du Vidal, 1993: 673Google Scholar
  29. 29.
    Provost JC, Funck-Brentano C, Rovei V, et al. Pharmacokinetic and pharmacodynamic interaction between toloxatone — a new reversible monoamine oxidase A inhibitor and oral tyramine in healthy subjects. Clin Pharmacol Ther 1992; 52: 384–94PubMedCrossRefGoogle Scholar
  30. 30.
    Da Prada M, Zurcher C, Wuthrich I, et al. On tyramine, food, beverages and the reversible MAO-A inhibitor, moclobem-ide. J Neural Transm 1988; 26: 31–56Google Scholar
  31. 31.
    Suchowersky O, DeVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990; 35(6): 571–2PubMedGoogle Scholar
  32. 32.
    Gilbar PJ, Brodribb TR, Downey N. Serotonin syndrome due to a moclobemide imipramine interaction. A previously unre-ported drug interaction? [abstract]. Aust J Hosp Pharm 1995; 25: 75Google Scholar
  33. 33.
    Spigset O, Mjorndal T. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ 1993; 306: 248PubMedCrossRefGoogle Scholar
  34. 34.
    Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses [letter]. Lancet 1993; 342: 1419PubMedCrossRefGoogle Scholar
  35. 35.
    DArcy PF. Life threatening interaction between pethidine and selegiline. Int Pharm J 1991; 5(3): 105–7Google Scholar
  36. 36.
    Zornberg GL, Vodkin JA, Cohen NM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 1991; 337: 246PubMedCrossRefGoogle Scholar
  37. 37.
    Waters CH. Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci 1994; 21: 259–61PubMedGoogle Scholar
  38. 38.
    White K, Simpson G. Combined MAOI — tricyclic anti-depressant treatment a re-evaluation. J Clin Psychopharmacol 1981; 1: 264–82PubMedCrossRefGoogle Scholar
  39. 39.
    Spiker DG, Pugh DP. Combining tricyclic and MAOI antidepressants. Arch Gen Psychiatry 1976; 33: 828–30PubMedCrossRefGoogle Scholar
  40. 40.
    Ananth J, Luchins D. A review of combined tricyclic and MAOI therapy. Compr Psychiatry 1977; 18(3): 221–30PubMedCrossRefGoogle Scholar
  41. 41.
    Vandel S, Bertschy G, Perault MC, et al. Minor and clinical non-significant interaction between toloxatone and amitriptyline. Eur J Clin Psychol 1993; 44, 97–9Google Scholar
  42. 42.
    Lefebvre H, Noblet C, Moore N, et al. Pseudophaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. J Clin Endocrinol. In pressGoogle Scholar
  43. 43.
    Lefebvre H, Richard R, Noblet C, et al. Life threatening pseudophaeochromocytoma after toloxatone terbutaline and phenylephrine. Lancet 1993; 341: 555–6PubMedCrossRefGoogle Scholar
  44. 44.
    Montastruc JL, Chamontin D, Senard JM, et al. Pseudophaeochromocytoma in Parkinsonian patient treated with fluoxetine and selegiline [letter]. Lancet 1993; 341: 555PubMedCrossRefGoogle Scholar
  45. 45.
    Schorelin N-P, Mayershon M, Hoevels B. Cimetidine alters the disposition kinetics of the monoamine oxidase inhibitor moclobemide. Clin Pharmacol Ther 1991; 49: 32–8CrossRefGoogle Scholar
  46. 46.
    Bennett WN, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 1983; 3(3): 155–93PubMedGoogle Scholar
  47. 47.
    Takyi BE. Excretion of drugs in human milk. Am J Hosp Pharm 1970; 28: 317–26Google Scholar
  48. 48.
    Annanth J. Side effects in the neonate from psychotropic agents excreted through breast feeding. Am J Psychiatry 1978; 135: 801–5Google Scholar
  49. 49.
    Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43: 561–96PubMedCrossRefGoogle Scholar
  50. 50.
    Preskorn SH. Recent pharmacologie advances in anti-depressant therapy for the elderly. Am J Med. 1993; 94(5A): 2S–12SPubMedGoogle Scholar
  51. 51.
    Baunbacher G, Hanson MS. Abuse of monoamine oxidase inhibitors. Am J Drug Alcohol Abuse 1992; 18(4): 399–406CrossRefGoogle Scholar
  52. 52.
    Vartopoulous D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 1991; 158: 856–7CrossRefGoogle Scholar
  53. 53.
    Cassidy S, Henry J. Fatal toxicity of anti-depressant drugs in overdosage. BMJ 1987; 295: 1021–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Martin G. Livingston
    • 1
  • Hilary M. Livingston
    • 2
  1. 1.University Department of Psychological Medicine, Academic Centre, Gartnavel Royal HospitalUniversity of GlasgowGlasgowScotland
  2. 2.Dykebar HospitalPaisleyScotland

Personalised recommendations